Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
															Search

		Submit


Tuberculosis (TB)


Facebook
        Twitter
        LinkedIn
        Syndicate





TB-Related Articles										Related Pages
										**2017 DTBE Publications**
Agizew T, Basotli J, Alexander H, Boyd R, Letsibogo G, Auld A, Nyirenda S, Tedla Z, Mathoma A, Mathebula U, Pals S, Date A, Finlay A. Higher-than-expected prevalence of non-tuberculous mycobacteria in HIV setting in Botswana: Implications for diagnostic algorithms using Xpert MTB/RIF assay.external icon PLoS One. 2017 Dec 22;12(12):e0189981. doi: 10.1371/journal.pone.0189981. eCollection 2017. PMID: 29272273.
Agizew T, Boyd R, Ndwapi N, Auld A, Basotli J, Nyirenda S, Tedla Z, Mathoma A, Mathebula U, Lesedi C, Pals S, Date A, Alexander H, Kuebrich T, Finlay A. Peripheral clinic versus centralized laboratory-based Xpert MTB/RIF performance: Experience gained from a pragmatic, stepped-wedge trial in Botswanaexternal icon. PLoS One. 2017 Aug 17;12(8):e0183237. doi: 10.1371/journal.pone.0183237. eCollection 2017. PMID: 28817643..Year202120202019201820172016201520142013Alsultan A, Savic R, Dooley KE, Weiner M, Whitworth W, Mac Kenzie WR, Peloquin CA; Tuberculosis Trials Consortium. Population Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis.external icon Antimicrob Agents Chemother. 2017 Mar 13. pii: AAC.02625-16. doi: 10.1128/AAC.02625-16. [Epub ahead of print]. PMID: 28289033.
Badal-Faesen S, Firnhaber C, Kendall MA, Wu X, Grinsztejn B, Escada RODS, Fernandez M, Hogg E, Sanne I, Johnson P, Alland D, Mazurek GH, Benator DA, Luetkemeyer AF; AIDS Clinical Trials Group A5295; Tuberculosis Trials Consortium Study 34 Teams. Impact of Larger Sputum Volume on Xpert<sup>®</sup> MTB/RIF Assay Detection of Mycobacterium tuberculosis in Smear-Negative Individuals with Suspected Tuberculosis.external icon J Clin Med. 2017 Aug 7;6(8). pii: E78. doi: 10.3390/jcm6080078. PMID: 28783093
Barry PM, Lowenthal P, True L, Henry L, Schack G, Wendorf K, Flood J, Shah N. Benefit of the Shorter MDR TB Treatment Regimen in California and Modified Eligibility Criteria.external icon Am J Respir Crit Care. 2017 Dec 1;196(11):1488-1489. doi: 10.1164/rccm.201701-0013LE. PMID: 28665681.
Belknap R, Holland D, Feng PJ, Millet JP, Caylà JA, Martinson NA, Wright A, Chen MP, Moro RN, Scott NA, Arevalo B, Miró JM, Villarino ME, Weiner M, Borisov AS; TB Trials Consortium iAdhere Study Team. Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial.external icon Ann Intern Med. 2017 Nov 21;167(10):689-697. doi: 10.7326/M17-1150. Epub 2017 Nov 7. PMID: 29114781.
Boyd R, Ford N, Padgen P, Cox H. Time to treatment for rifampicin-resistant tuberculosis: systematic review and meta-analysis.external icon Int J Tuberc Lung Dis. 2017 Nov 1;21(11):1173-1180. doi: 10.5588/ijtld.17.0230. PMID: 29037299.
Breedlove B, Chorba T. Elaborate details, hidden surprises. Emerg Infect Dis 2017; 23:1229–30.
Castro KG, Marks SM, Hill AN, Chen MP, Miramontes R, Winston CA, LoBue PA. In reply.external icon Int J Tuberc Lung Dis. 2017 Jan 1;21(1):120-121. doi: 10.5588/ijtld.16.0708-2. No abstract available. PMID: 28157476.
Cavanaugh JS, Jou R, Wu MH, Dalton T, Kurbatova E, Ershova J, Cegielski JP; Global PETTS Investigators. Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.external icon J Antimicrob Chemother. 2017 Jun 1;72(6):1678-1687. doi: 10.1093/jac/dkx022. PMID: 28333192.
CDC (Olano-Soler H, Thomas, D, Joglar O, Rios K, Torres-Rodríguez M, Duran-Guzman G,   Chorba T). *Notes from the Field: Use of Asynchronous Video Directly Observed Therapy for Treatment of Tuberculosis and Latent Tuberculosis Infection in a Long-Term-Care Facility – Puerto Rico, 2016-2017.external icon* MMWR 2017 Dec 22;66(50):1386–1387. doi: 10.15585/mmwr.mm6650a5.
CDC (Morris S, Miner M, Rodriguez T, Stancil, R, Wiltz-Beckham D, Chorba T). *Notes from the Field: Tuberculosis Control Activities After Hurricane Harvey — Texas, 2017*. Weekly 2017 December 15;66(49);1362–1363.
CDC (Schmit KM, Wansaula Z, Pratt R, Price SF, Langer, AJ). Tuberculosis — United States, 2016. MMWR 2017 March 24; 66(11);289–294. doi: http://dx.doi.org/10.15585/mmwr.mm6611a2external icon.
CDC (Tsang CA, Langer AJ, Navin TR, Armstrong, LR).Tuberculosis Among Foreign-Born Persons Diagnosed ≥10 Years After Arrival in the United States, 2010–2015. MMWR 2017 March 24; 66(11);295–298. doi: http://dx.doi.org/10.15585/mmwr.mm6611a3external icon.
Chorba T, Jereb J. Keeping It in the Family: the Childhood Burden of Tuberculosisexternal icon. Emerging Infectious Diseases. 2017 Mar;23(3):561-562. doi:10.3201/eid2303.AC2303.
Garzan A, Willby MJ, Ngo HX, Gajadeera CS, Green KD, Holbrook SYL, Hou C, Posey JE, Tsodikov OV, Garneau-Tsodikova S. Combating Enhanced Intracellular Survival (Eis)-Mediated Kanamycin Resistance of Mycobacterium tuberculosis by Novel Pyrrolo[1,5-a]pyrazine-Based Eis Inhibitors. ACS Infect Dis.external icon 2017 Apr 14;3(4):302-309. doi: 10.1021/acsinfecdis.6b00193. Epub 2017 Feb 17. PMID: 28192916.
Hall EW, Morris SB, Moore BK, Erasmus L, Odendaal R, Menzies H, van der Walt M, Smith SE. Treatment Outcomes of Children with HIV Infection and Drug-Resistant TB in Three Provinces in South Africa, 2005-2008.external icon Pediatr Infect Dis J. 2017 Dec;36(12):e322-e327. doi: 10.1097/INF.0000000000001691. PMID: 28746263.
Hannah HA, Miramontes R, Gandhi NR. Sociodemographic and Clinical Risk Factors Associated With Tuberculosis Mortality in the United States, 2009-2013.external icon Public Health Rep. 2017 May/Jun;132(3):366-375. doi: 10.1177/0033354917698117. Epub 2017 Apr 10. PMID: 28394707.
Jeffries C, Lobue P, Chorba T, Metchock B, Kashef I. Role of the Health Department in Tuberculosis Prevention and Control-Legal and Public Health Considerations.external icon Microbiol Spectr. 2017 Mar;5(2). doi: 10.1128/microbiolspec.TNMI7-0034-2016. PMID: 28256190.
Jones JM, Armstrong LR. Delayed and Unreported Drug-Susceptibility Testing Results in the US National Tuberculosis Surveillance System, 1993-2014.external icon Public Health Rep. 2017 Jul/Aug;132(4):480-487. doi: 10.1177/0033354917708989. Epub 2017 Jun 6. PMID: 28586626.
Kay A, Barry PM, Annambhotla P, Greene C, Cilnis M, Chin-Hong P, Arger N, McNitt L, Neidlinger N, Shah N, Basavaraju SV, Kuehnert M, Shaw T. Solid Organ Transplant-Transmitted Tuberculosis Linked to a Community Outbreak – California, 2015.external icon MMWR Morb Mortal Wkly Rep. 2017 Aug 4;66(30):801-805. doi: 10.15585/mmwr.mm6630a1. PMID: 28771459.
Khan AD, Dean HD. Tuberculosis among adults and the determinants of health [Internet]. Oxford Bibliographies 2017; http://www.oxfordbibliographies.com/view/document/obo-9780199756797/obo-9780199756797-0170.xmlexternal icon. doi: 10.1093/obo/9780199756797-0170.****
Lempp JM, Zajdowicz MJ, Hankinson AL, Toney SR, Keep LW, Mancuso JD, Mazurek GH. Assessment of the QuantiFERON-TB Gold In-Tube test for the detection of Mycobacterium tuberculosis infection in United States Navy recruits.external icon PLoS One. 2017 May 17;12(5):e0177752. doi: 10.1371/journal.pone.0177752. eCollection 2017. PMID: 28545136.
Levanon Seligson A, Parvez FM, Lim S, Singh T, Mavinkurve M, Harris TG, Kerker BD. Public Health and Vulnerable Populations: Morbidity and Mortality Among People Ever Incarcerated in New York City Jails, 2001 to 2005.external icon J Correct Health Care. 2017 Oct;23(4):421-436. doi: 10.1177/1078345817727527. Epub 2017 Oct 5. PMID: 28982284.
Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, Keane J, Lewinsohn DA, Loeffler AM, Mazurek GH, O’Brien RJ, Pai M, Richeldi L, Salfinger M, Shinnick TM, Sterling TR, Warshauer DM, Woods GL. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children.external icon Clin Infect Dis. 2017 Jan 15;64(2):111-115. doi: 10.1093/cid/ciw778. PMID: 28052967.
LoBue PA, Mermin JH. Latent tuberculosis infection: the final frontier of tuberculosis elimination in the USA.external icon Lancet Infect Dis. 2017 Oct;17(10):e327-e333. doi: 10.1016/S1473-3099(17)30248-7. Epub 2017 May 8. PMID: 28495525.
Macaraig M, Lobato MN, McGinnis Pilote K, Wegener D. A National Survey on the Use of Electronic Directly Observed Therapy for Treatment of Tuberculosis.external icon J Public Health Manag Pract. 2017 Jul 7. doi: 10.1097/PHH.0000000000000627. PMID: 28692611.
Malekinejad M, Parriott A, Viitanen AP, Horvath H, Marks SM, Kahn JG. Yield of community-based tuberculosis targeted testing and treatment in foreign-born populations in the United States: A systematic review.external icon PLoS One. 2017 Aug 7;12(8):e0180707. doi: 10.1371/journal.pone.0180707. eCollection 2017. PMID: 28786991.
Marks SM, Hirsch-Moverman Y, Seaworth B, Salcedo K, Graviss EA, Armstrong L, Armitige L, Flood J, Mase S. Outcomes and costs of out-patient MDR-TB care in the USA.external icon Int J Tuberc Lung Dis. 2017 Apr 1;21(4):477-478. doi: 10.5588/ijtld.17.0009. No abstract available. PMID: 28284273.
Marks SM, Mase SR, Bamrah Morris S. Systematic Review, Meta-Analysis, and Cost Effectiveness of Treatment of Latent Tuberculosis Infection to Reduce Progression to Multidrug-Resistant Tuberculosis.external icon Clin Infect Dis. 2017 Jun 15;64(12):1670-1677. doi: 10.1093/cid/cix208. PMID: 28329197.
Mathema B, Andrews JR, Cohen T, Borgdorff MW, Behr M, Glynn JR, Rustomjee R, Silk BJ, Wood R. Drivers of Tuberculosis Transmission.external icon J Infect Dis. 2017 Nov 3;216(suppl_6):S644-S653. doi: 10.1093/infdis/jix354. PMID: 29112745.
McDaniel CJ, Chitnis AS, Barry PM, Shah N. Tuberculosis trends in California correctional facilities, 1993-2013.external icon Int J Tuberc Lung Dis. 2017 Aug 1;21(8):922-929. doi: 10.5588/ijtld.16.0855. PMID: 28786801.
Mindra G, Wortham JM, Haddad MB, Powell KM. Tuberculosis Outbreaks in the United States, 2009-2015.external icon Public Health Rep. 2017 Mar/Apr;132(2):157-163. doi: 10.1177/0033354916688270. Epub 2017 Feb 1. PMID: 28147211.
Miotto P, Tessema B, Tagliani E, Chindelevitch L, Starks AM, Emerson C, Hanna D, Kim PS, Liwski R, Zignol M, Gilpin C, Niemann S, Denkinger CM, Fleming J, Warren RM, Crook D, Posey J, Gagneux S, Hoffner S, Rodrigues C, Comas I, Engelthaler DM, Murray M, Alland D, Rigouts L, Lange C, Dheda K, Hasan R, Ranganathan UDK, McNerney R, Ezewudo M, Cirillo DM, Schito M, Köser CU, Rodwell TC. A standardised method for interpreting the association between mutations and phenotypic drug resistance in <i>Mycobacterium tuberculosis</i>.external icon Eur Respir J. 2017 Dec 28;50(6). pii: 1701354. doi: 10.1183/13993003.01354-2017. Print 2017 Dec. PMID: 29284687.
Morlock GP, Tyrrell FC, Baynham D, Escuyer VE, Green N, Kim Y, Longley-Olson PA, Parrish N, Pennington C, Tan D, Austin B, Posey JE. Using reduced inoculum densities of *Mycobacterium tuberculosis* in MGIT pyrazinamide susceptibility testing to prevent false-resistant results and improve accuracy: a multi-center evaluation. Tuberc Res Treat.external icon 2017;2017:3748163. doi: 10.1155/2017/3748163. Epub 2017 Nov 8. PMID: 29250443.
Moro RN, Sterling TR, Saukkonen J, Vernon A, Horsburgh CR, Chaisson RE, Hamilton CD, Villarino ME, Goldberg S. Factors associated with non-completion of follow-up: 33-month latent tuberculous infection treatment trial. Int J Tuberc Lung Dis.external icon 2017 Mar 1;21(3):286-296. doi: 10.5588/ijtld.16.0469. PMID: 28087928.
Owusu-Edusei K, Marks SM, Miramontes R, Stockbridge EL, Winston CA. Tuberculosis hospitalization expenditures per patient from private health insurance claims data, 2010-2014.external icon Int J Tuberc Lung Dis. 2017 Apr 1;21(4):398-404. doi: 10.5588/ijtld.16.0587. PMID: 28284254.
Owusu-Edusei K, Stockbridge EL, Winston CA, Kolasa M, Miramontes R. Tuberculin skin test and interferon-gamma release assay use among privately insured persons in the United States.external icon Int J Tuberc Lung Dis. 2017 Mar 28. doi: 10.5588/ijtld.16.0617. [Epub ahead of print]. PMID: 28351463.
Owusu-Edusei Jr. K, Winston CA, Marks SM, Langer AJ, Miramontes R. Tuberculosis Test Usage and Medical Expenditures from Outpatient Insurance Claims Data, 2013.external icon Tuberc Res Treat. 2017;2017:3816432. doi: 10.1155/2017/3816432. Epub 2017 Oct 23. PMID: 29326845.
Parmer J, Allen L, Walton W. CE: Tuberculosis: A New Screening Recommendation and an Expanded Approach to Elimination in the United States.external icon Am J Nurs. 2017 Jul 12. doi: 10.1097/01.NAJ.0000521946.45448.90. [Epub ahead of print]. PMID: 28704234.
Powell KM, VanderEnde DS, Holland DP, Haddad MB, Yarn B, Yamin AS, Mohamed O, Sales RF, DiMiceli LE, Burns-Grant G, Reaves EJ, Gardner TJ, Ray SM. Outbreak of Drug-Resistant Mycobacterium tuberculosis Among Homeless People in Atlanta, Georgia, 2008-2015.external icon Public Health Rep. 2017 Mar/Apr;132(2):231-240. doi: 10.1177/0033354917694008. PMID: 28257261.
Reaves EJ, Shah NS, France AM, Morris SB, Kammerer S, Skarbinski J, Bradley H. Latent tuberculous infection testing among HIV-infected persons in clinical care, United States, 2010-2012.external icon Int J Tuberc Lung Dis. 2017 Oct 1;21(10):1118-1126. doi: 10.5588/ijtld.17.0041. PMID: 28911355.
Salinas JL, Armstrong LR, Silk BJ, Haddad MB, Cegielski JP. Factors Associated with All-Cause Mortality among Patients with Multidrug-Resistant Tuberculosis – United States, 1993-2013.external icon Clin Infect Dis. 2017 Jul 29. doi: 10.1093/cid/cix667. [Epub ahead of print.] PMID: 29020169.
Sandul AL, Nwana N, Holcombe JM, Lobato MN, Marks S, Webb R, Wang SH, Stewart B, Griffin P, Hunt G, Shah N, Marco A, Patil N, Mukasa L, Moro RN, Jereb J, Mase S, Chorba T, Bamrah-Morris S, Ho CS. High Rate of Treatment Completion in Program Settings with 12-Dose Weekly Isoniazid and Rifapentine (3HP) for Latent Mycobacterium tuberculosis Infection.external icon Clin Infect Dis. 2017 May 30. doi: 10.1093/cid/cix505. [Epub ahead of print]. PMID: 28575208.
Savic RM, Weiner M, MacKenzie WR, Engle M, Whitworth WC, Johnson JL, Nsubuga P, Nahid P, Nguyen NV, Peloquin CA, Dooley KE, Dorman SE; Tuberculosis Trials Consortium of the Centers for Disease Control and Prevention. Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials.external icon Clin Pharmacol Ther. 2017 Aug;102(2):321-331. doi: 10.1002/cpt.634. Epub 2017 Mar 2. PMID: 28124478.
Scott C, Cavanaugh JS, Silk BJ, Ershova J, Mazurek GH, LoBue PA, Moonan PK. Comparison of Sputum-Culture Conversion for Mycobacterium bovis and M. tuberculosis.external icon Emerg Infect Dis. 2017 Mar;23(3):456-462. doi: 10.3201/eid2303.161916. PMID: 28221125.
Scott C, Mangan J, Tillova Z, Jensen PA, Ahmedov S, Ismoilova J, Trusov A. Evaluation of the Tuberculosis Infection Control Training Center, Tajikistan, 2014-2015.external icon Int J Tuberc Lung Dis. 2017 May 1;21(5):579-585. doi: 10.5588/ijtld.16.0518. PMID: 28399974.
Shah NS, Flood-Bryzman A, Jeffries C, Scott J. Towards a Generation Free of Tuberculosis: TB disease and Infection in Individuals of College Age in the United States.external icon J Am Coll Health. 2018 Jan;66(1):17-22. doi: 10.1080/07448481.2017.1363765. Epub 2017 Sep 15. PMID: 28800282.
Sharma A, Hill A, Kurbatova E, van der Walt M, Kvasnovsky C, Tupasi TE, Caoili JC, Gler MT, Volchenkov GV, Kazennyy BY, Demikhova OV, Bayona J, Contreras C, Yagui M, Leimane V, Cho SN, Kim HJ, Kliiman K, Akksilp S, Jou R, Ershova J, Dalton T, Cegielski P; Global Preserving Effective TB Treatment Study Investigators. Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa: a mathematical modelling study.external icon Lancet Infect Dis. 2017 May 9. pii: S1473-3099(17)30247-5. doi: 10.1016/S1473-3099(17)30247-5. [Epub ahead of print]. PMID: 28499828.
Shin SS, Modongo C, Boyd R, Caiphus C, Kuate L, Kgwaadira B, Zetola NM. High Treatment Success Rates Among HIV-Infected Multidrug-Resistant Tuberculosis Patients After Expansion of Antiretroviral Therapy in Botswana, 2006-2013.external icon J Acquir Immune Defic Syndr. 2017 Jan 1;74(1):65-71. PMID: 27552155.
Shrestha S, Hill AN, Marks SM, Dowdy DW. Comparing Drivers and Dynamics of Tuberculosis (TB) in California, Florida, New York and Texas.external icon Am J Respir Crit Care Med. 2017 May 5. doi: 10.1164/rccm.201702-0377OC. [Epub ahead of print]. PMID: 28475845.
Sigal GB, Segal MR, Mathew A, Jarlsberg L, Wang M, Barbero S, Small N, Haynesworth K, Davis JL, Weiner M, Whitworth WC, Jacobs J, Schorey J, Lewinsohn DM, Nahid P. Biomarkers of Tuberculosis Severity and Treatment Effect: A Directed Screen of 70 Host Markers in a Randomized Clinical Trial.external icon EBioMedicine. 2017 Oct 24. pii: S2352-3964(17)30417-6. doi: 10.1016/j.ebiom.2017.10.018. [Epub ahead of print]. PMID: 29100778.
Sinha SK, Saxena A, Mishra V, Volkmann T, Kumar AMV, Nair SA, Moonan PK, Oeltmann JE, Chadha VK. Integration and decentralisation of TB-HIV services increases HIV testing of TB cases in Rajasthan, India.external icon Public Health Action. 2017 Mar 21;7(1):71-73. doi: 10.5588/pha.16.0060. PMID: 28775947.
Smith SE, Pratt R, Trieu L, Barry PM, Thai DT, Ahuja SD, Shah S. Epidemiology of pediatric multidrug-resistant tuberculosis in the United States, 1993-2014.external icon Clin Infect Dis. 2017 Jun 19. doi: 10.1093/cid/cix561. [Epub ahead of print]. PMID: 28633501.
Stafford C, Atkinson-Dunn R, Buss SN, Dalton T, Gibson D, Johnston S, King E, Grace Lin SY, Mitchell KK, Murtaugh WA, Sease H, Southern TR, Tans-Kersten JL, Travanty EA, Triplett LR, Wroblewski K, Starks AM. The Use of a Shared Services Model for Mycobacteriology Testing: Lessons Learned.external icon Public Health Rep. 2017 Jan 1:33354917743498. doi: 10.1177/0033354917743498. [Epub ahead of print]. PMID: 29258383.
Stockbridge EL, Miller TL, Carlson EK, Ho C. Tuberculosis Prevention in the Private Sector: Using Claims-Based Methods to Identify and Evaluate Latent Tuberculosis Infection Treatment With Isoniazid Among the Commercially Insured.external icon J Public Health Manag Pract. 2017 Oct 27. doi: 10.1097/PHH.0000000000000628. [Epub ahead of print]. PMID: 29084120.
Tasillo A, Salomon JA, Trikalinos TA, Horsburgh CR Jr, Marks SM, Linas BP. Cost-effectiveness of Testing and Treatment for Latent Tuberculosis Infection in Residents Born Outside the United States With and Without Medical Comorbidities in a Simulation Model.external icon JAMA Intern Med. 2017 Oct 16. doi: 10.1001/jamainternmed.2017.3941. [Epub ahead of print]. PMID: 29049814.
Teeter LD, Kammerer JS, Ghosh S, Nguyen DTM, Vempaty P, Tapia J, Miramontes R, Cronin WA, Graviss EA; Tuberculosis Epidemiologic Studies Consortium. Evaluation of 24-locus MIRU-VNTR genotyping in Mycobacterium tuberculosis cluster investigations in four jurisdictions in the United States, 2006-2010.external icon Tuberculosis (Edinb). 2017 Sep;106:9-15. doi: 10.1016/j.tube.2017.05.003. Epub 2017 May 25. PMID: 28802410.
Thai LH, Nhat L M, Shah N, Lyss S, Ackers M. Sensitivity, completeness and agreement of the tuberculosis electronic system in Ho Chi Minh City, Viet Nam. Public Health Action.external icon 2017 Dec 21;7(4):294-298. doi: 10.5588/pha.17.0081. PMID: 29584795.
Tsang CA, Langer AJ, Navin TR, Armstrong LR. Tuberculosis Among Foreign-Born Persons Diagnosed ≥10 Years After Arrival in the United States, 2010-2015.external icon Am J Transplant. 2017 May;17(5):1414-1417. doi: 10.1111/ajt.14300. PMID: 28453231.
Tupasi T, Garfin AM, Mangan JM, Orillaza-Chi R, Naval LC, Balane GI, Basilio R, Golubkov A, Joson ES, Lew WJ, Lofranco V, Mantala M, Pancho S, Sarol JN, Blumberg A, Burt D, Kurbatova EV. Multidrug-resistant tuberculosis patients’ views of interventions to reduce treatment loss to follow-up.external icon Int J Tuberc Lung Dis. 2017 Jan 1;21(1):23-31. doi: 10.5588/ijtld.16.0433. PMID: 28157461.
Volkmann T, Nguyen B, Anyalechi EG, Chapman Hedges KN, Van Anh H, Tue PQ, Nhung NV, Click ES. Comparison of HIV Testing among Children and Adults with Tuberculosis, Vietnam.external icon J Tuberc Res. 2017 Dec;5(4):292-297. doi: 10.4236/jtr.2017.54030. Epub 2017 Dec 29. PMID: 29349098.
Willby MJ, Wijkander M, Havumaki J, Johnson K, Werngren J, Hoffner S, Denkinger CM, Posey JE. Detection of Mycobacterium tuberculosis pncA mutations by the NIPRO GenoscholarTM⋅PZA-TB II as compared to conventional sequencing. Antimicrob Agents Chemother.external icon 2017 Oct 30. pii: AAC.01871-17. doi: 10.1128/AAC.01871-17. [Epub ahead of print]. PMID: 29084743.
Winston CA, Stone ND. Detect to Prevent: Evaluating Testing and Treatment Practices for Latent Tuberculosis Infection in Long-Term Care Facilities.external icon J Am Geriatr Soc. 2017 Mar 17. doi: 10.1111/jgs.14752. [Epub ahead of print]. No abstract available. PMID: 28306136.
Worrell MC, Kramer M, Yamin A, Ray SM, Goswami ND. Use of Activity Space in a Tuberculosis Outbreak: Bringing Homeless Persons Into Spatial Analyses.external icon Open Forum Infect Dis. 2017 Jan 9;4(1):ofw280. doi: 10.1093/ofid/ofw280. eCollection 2017 Winter. PMID: 28480272.
Wortham JM, Goggin M, Mora C, Vandehey L, Manangan L, Powell KM. Acute kidney injury during treatment for latent tuberculous infection with rifampin.external icon Int J Tuberc Lung Dis. 2017 May 1;21(5):596-597. doi: 10.5588/ijtld.17.0003. PMID: 28399977.
**
*Last updated March 5, 2018*
							
					
						Page last reviewed:  June 16, 2017					Content source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention homeTuberculosis
Basic TB Factsplus icon
How TB Spreads
Latent TB Infection and TB Disease
Signs & Symptoms
TB Risk Factors
Exposure to TB
TB Prevention
Vaccines
TB & HIV Coinfection
TB and Diabetes
TB Terms
Personal Storiesplus icon
Stories by Topic
Archived Stories
Testing & Diagnosisplus icon
Who Should be Tested
Testing for TB Infection
Testing in BCG-Vaccinated Persons
TB Screening and Testing of Health Care Personnel
Testing During Pregnancy
Diagnosing latent TB infection and TB disease
Treatmentplus icon
Deciding When to Treat Latent TB Infection
Treatment Regimens for Latent TB Infection (LTBI)
Treatment for TB Disease
Adverse Events
TB Treatment of Persons Living with HIV
TB Treatment and Pregnancy
TB Treatment for Children
Drug-Resistant TB
Researchplus icon
TB Epidemiologic Studies Consortiumplus icon
Research Projects
Publications
TB Trials Consortiumplus icon
Study Descriptions
Background
Behavioral & Social Science Research
Health Care Settingsplus icon
TB Infection Control in Health Care Settings
Resources for TB Screening and Testing of Health Care Personnelplus icon
Frequently Asked Questions
TB in Specific Populationsplus icon
Health Disparities
Asian Persons
Black or African American Persons
Hispanic or Latino Persons
Children
Pregnancy
Correctional Facilities
People Experiencing Homelessness
International Travelers
Laboratory Informationplus icon
Drug Susceptibility Testing
False-Positive Investigation Toolkit
Interim Laboratory Biosafety Guidance for XDR *Mycobacterium* tuberculosis strains
Model Performance Evaluation Program (MPEP)
Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus icon
Executive Summary
Introduction
Background on Tests for Molecular Detection of DR
General Considerations and Principles for a Molecular DR Testing Service
Possible Scenarios and Scope of Testing for a Molecular DR Testing Service
Research Needs
General Recommendations of the Expert Panel
Communication Plan for the Report
Recommendations
References
Panel Members and CDC Participants
Appendix 1
Appendix 2
Appendix 3
The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus icon
General Considerations
General Recommendations of the Expert Panel
Recommendations to ACET, CDC, DTBE
Data & Statisticsplus icon
TB Incidence in the United States
Reported TB in the US, 2019 Surveillance Report
Trends in Tuberculosis 2019
Tuberculosis in the United States, 2019 (Slide Set)
Archived Surveillance Reports and Slide Sets
2019 State and City Report
Archived State and City Reports
Professional Resources & Toolsplus icon
Tools for Healthcare Providersplus icon
Interactive Core Curriculum on Tuberculosis: What the Clinician Should Know
Resources for TB Programsplus icon
Notice of Funding Opportunity (NOFO)
Program Evaluation
TB Centers of Excellence
TB Community Engagement Network
Publications & Productsplus icon
Patient and Public Materials
Fact Sheetsplus icon
General
Data & Statistics
Drug-Resistant TB
Infection Control & Prevention
TB in Specific Populations
Treatment
Testing & Diagnosis
Vaccines & Immunizations
Guidelinesplus icon
Control & Elimination
Drug-Resistant TB
Infection Control & Prevention
Laboratory & Genotyping
TB & HIV
TB in Specific Populations
Testing & Diagnosis
Treatment
Vaccines & Immunizations
Archived TB Guidelines
Guides & Toolkitsplus icon
Aggregate Reports
CDC TB Surveillance Training
Core Curriculum
Effective TB Interviewing for Contact Investigation
Ethnographic Guides
False-Positive Investigation Toolkit
Forging Partnerships to Eliminate TB
Guide to Application of Genotyping
LTBI: A Guide for Primary Health Care Providers
Mantoux Tuberculin Skin Testing Products
Report of Verified Case of Tuberculosis (RVCT)
Self-Study Modules
TB Contact Investigation Interviewing Skills Course
TB eDOT Toolkit
Understanding the TB Cohort Review Process
Newslettersplus icon
TB Notes, No. 1, 2021
TB Notes, No. 4, 2020
TB Notes, No. 3, 2020
TB Notes, No. 2, 2020
TB Notes, No. 1, 2020
TB Notes, No. 4, 2019
TB Notes, No. 3, 2019
TB Notes, No. 2, 2019
TB Notes, No. 1, 2019
TB Notes, No. 6, 2018
TB Notes, No. 5, 2018
TB Notes, No. 4, 2018
TB Notes, No. 3, 2018
TB Notes, No. 2, 2018
TB Notes, No. 1, 2018
TB Notes, No. 5, 2017
TB Notes, No. 4, 2017
TB Notes, No. 3, 2017
TB Notes, No. 2, 2017
TB Notes, No. 1, 2017
TB Notes, No. 5, 2016
TB Notes, No. 4, 2016
TB Notes, No. 3, 2016
TB Notes, No. 2, 2016
TB Notes, No. 1, 2016
Pamphlets, Brochures, Bookletsplus icon
Questions and Answers
Patient Education Series
Tuberculosis – Get the Facts
Tuberculosis – The Connection between TB and HIV
12-Dose Regimen for Latent TB Infection-Patient Education Brochure
Postersplus icon
Mantoux Tuberculin Skin Test Wall Chart
World TB Day
Think TB
Stop TB
Take on TB
Reports & Articlesplus icon
DTBE Authored Journal Articles
Tuberculosis Laboratory Aggregate Reports
Slide Setsplus icon
Introduction to Tuberculosis
Epidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016
Self-Study Modules on Tuberculosis, 1-5 Slide Sets
The Tuberculosis (TB) in Correctional Settingsplus icon
Facilitator Guide
Introduction to TB Genotyping
Epidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017
Prevention and Control of Tuberculosis in Correctional and Detention Facilities
Guidelines for Preventing the Transmission of M. TB in Health care Settings
Investigation of Contacts of Persons with Infectious TB
Epidemiology of Pediatric Tuberculosis in the United States
Targeted Tuberculosis Testing and Treatment of Latent Tuberculosis Infection
Electronic Tools & Resources
Web-Based Courses & Webinarsplus icon
TB 101 for Health Care Workersplus icon
TB 101
Interactive Core Curriculum
Content Syndication
Infographicsplus icon
Social Media Graphics
Customizable Take on TB Infographic with Instructions
Events
World TB Dayplus icon
Resources
U.S. TB Championsplus icon
2021 CDC U.S. TB Elimination Champions
2020 CDC U.S. TB Elimination Champions
2019 CDC U.S. TB Elimination Champions
2018 CDC U.S. TB Elimination Champions
2017 CDC U.S. TB Elimination Champions
2016 CDC U.S. TB Elimination Champions
News & Events
History
Featuresplus icon
TB Risk Factors
Treating Latent TB Infection with Short-Course Regimens
World Tuberculosis (TB) Day 2021
World Tuberculosis (TB) Day 2020
Linksplus icon
State TB Control Offices
About Usplus icon
Mission Statement and Activitiesplus icon
DTBE Strategic Plan
National TB Program Objectives
Organization Chart
Advisory Groupsplus icon
Federal TB Task Force


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue